Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 5/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 5/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 5/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22412342 | 1.00 | SLC6A12 (0.34) | SLC6A12SLC6A11SLC6A13SLC6A1GABRA5 | |
| SCHEMBL20722063 | 0.81 | FFAR4 (0.33) | MAPTFFAR4 | |
| SCHEMBL20722064 | 0.81 | FFAR4 (0.33) | MAPTFFAR4 | |
| SCHEMBL18327254 | 0.80 | SLC6A12 (0.34) | SLC6A12SLC6A11SLC6A13SLC6A1GABRA5 | |
| SCHEMBL20722109 | 0.78 | PTGIR (0.38) | — | |
| SCHEMBL20722108 | 0.78 | PTGIR (0.38) | — | |
| SCHEMBL20722117 | 0.77 | — | — | |
| SCHEMBL20721957 | 0.74 | ATF4 (0.39) | — | |
| SCHEMBL20722106 | 0.74 | ATF4 (0.39) | — | |
| SCHEMBL22411998 | 0.74 | APLNR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114025844-B | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114025844-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-3938038-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | ABBVIE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299246-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020186199-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851073-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | PTPN1, PTPN2, PTPN18 | SLC6A12 4767/4885SLC6A11 4764/4885SLC6A13 4783/4885 |
| US-20200299246-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | SLC6A12 4767/4885SLC6A11 4764/4885SLC6A13 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.